119 related articles for article (PubMed ID: 23724156)
41. Early sorafenib induction after transarterial chemoembolization for unresectable hepatocellular carcinoma: Can sorafenib after TACE improve loco-regional control?
Tamai T; Kumagai K; Sakae H; Onishi H; Tabu K; Tabu E; Muromachi K; Saishoji A; Oda K; Mawatari S; Moriuchi A; Sakurai K; Ido A
Mol Clin Oncol; 2017 Dec; 7(6):1135-1141. PubMed ID: 29285389
[TBL] [Abstract][Full Text] [Related]
42. Transarterial injection of recombinant human type-5 adenovirus H101 in combination with transarterial chemoembolization (TACE) improves overall and progressive-free survival in unresectable hepatocellular carcinoma (HCC).
Lin XJ; Li QJ; Lao XM; Yang H; Li SP
BMC Cancer; 2015 Oct; 15():707. PubMed ID: 26470869
[TBL] [Abstract][Full Text] [Related]
43. Prognostic Survival Factors of Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.
Rohan T; Uher M; Matkulčík P; Zavadil J; Ostřížková L; Kiss I; Andrašina T; Válek V
Klin Onkol; 2020; 33(3):214-219. PubMed ID: 32683878
[TBL] [Abstract][Full Text] [Related]
44. Transarterial chemoembolization combined with iodine 125 seeds versus transarterial chemoembolization combined with radiofrequency ablation in the treatment of early- and intermediate-stage hepatocellular carcinoma.
Chen L; Kan X; Sun T; Ren Y; Cao Y; Yan L; Liang B; Xiong B; Zheng C
BMC Gastroenterol; 2020 Jun; 20(1):205. PubMed ID: 32600349
[TBL] [Abstract][Full Text] [Related]
45. Repeated transarterial chemoembolization with epirubicin-loaded superabsorbent polymer microspheres vs. conventional transarterial chemoembolization for hepatocellular carcinoma.
Fukushima T; Morimoto M; Kobayashi S; Ueno M; Sano Y; Kawano K; Asama H; Nagashima S; Maeda S
Mol Clin Oncol; 2021 Jun; 14(6):119. PubMed ID: 33903825
[TBL] [Abstract][Full Text] [Related]
46. Transarterial chemoembolization in unresectable hepatocellular carcinoma--assessing the factors affecting the survival: An audit from a tertiary care center in northern India.
Agarwal A; Yadav AK; Kumar A; Gupta S; Panwala HK; Redhu N; Hariprasad S; Ranjan P; Arora A; Gupta A
Indian J Gastroenterol; 2015 Mar; 34(2):117-26. PubMed ID: 25937484
[TBL] [Abstract][Full Text] [Related]
47. Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Huang K; Zhou Q; Wang R; Cheng D; Ma Y
J Gastroenterol Hepatol; 2014 May; 29(5):920-5. PubMed ID: 24224722
[TBL] [Abstract][Full Text] [Related]
48. Super-selective transarterial chemoembolization of hepatocellular carcinoma with doxorubicin-eluting beads sized 40-75 microns: assessment of efficacy and safety.
Ballı HT; Aikimbaev K
Diagn Interv Radiol; 2020 Sep; 26(5):482-487. PubMed ID: 32815520
[TBL] [Abstract][Full Text] [Related]
49. Combination Therapy of Radiofrequency Ablation and Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Retrospective Study.
Tang C; Shen J; Feng W; Bao Y; Dong X; Dai Y; Zheng Y; Zhang J
Medicine (Baltimore); 2016 May; 95(20):e3754. PubMed ID: 27196501
[TBL] [Abstract][Full Text] [Related]
50. Transarterial chemoembolization with cisplatin as second-line treatment for hepatocellular carcinoma unresponsive to chemoembolization with epirubicin-Lipiodol emulsion.
Maeda N; Osuga K; Higashihara H; Tomoda K; Mikami K; Nakazawa T; Nakamura H; Tomiyama N
Cardiovasc Intervent Radiol; 2012 Feb; 35(1):82-9. PubMed ID: 21203761
[TBL] [Abstract][Full Text] [Related]
51. Survival in unresectable AJCC stage I and II HCC and the effect of DEB-TACE: SEER versus tertiary cancer center cohort study.
Xing M; Kokabi N; Prajapati HJ; Close O; Ludwig JM; Kim HS
J Comp Eff Res; 2016 Mar; 5(2):141-54. PubMed ID: 26946950
[TBL] [Abstract][Full Text] [Related]
52. Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial.
Seinstra BA; Defreyne L; Lambert B; Lam MG; Verkooijen HM; van Erpecum KJ; van Hoek B; van Erkel AR; Coenraad MJ; Al Younis I; van Vlierberghe H; van den Bosch MA
Trials; 2012 Aug; 13():144. PubMed ID: 22913492
[TBL] [Abstract][Full Text] [Related]
53. Efficacy And Safety Of Raltitrexed Plus Oxaliplatin-Based Transarterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma.
Shao W; Li C; Tang J; Song J; Li Z; Sun J; Xu Y; Zheng Z; Cao J; Zhang L
Cancer Manag Res; 2019; 11():9863-9869. PubMed ID: 31819623
[TBL] [Abstract][Full Text] [Related]
54. Transarterial chemoembolization combined with Jie-du granule preparation improves the survival outcomes of patients with unresectable hepatocellular carcinoma.
Zhao H; Zhai X; Chen Z; Wan X; Chen L; Shen F; Ling C
Oncotarget; 2017 Jul; 8(28):45234-45241. PubMed ID: 28423370
[TBL] [Abstract][Full Text] [Related]
55. Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States.
Reyes DK; Vossen JA; Kamel IR; Azad NS; Wahlin TA; Torbenson MS; Choti MA; Geschwind JF
Cancer J; 2009; 15(6):526-32. PubMed ID: 20010173
[TBL] [Abstract][Full Text] [Related]
56. Outcomes of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma: A tertiary center experience.
Tahir M; Mustafa K; Ali M; Khalid D
Pak J Med Sci; 2024 Jul; 40(6):1196-1200. PubMed ID: 38952507
[TBL] [Abstract][Full Text] [Related]
57. Reason of Discontinuation After Transarterial Chemoembolization Influences Survival in Patients with Hepatocellular Carcinoma.
Labeur TA; Takkenberg RB; Klümpen HJ; van Delden OM
Cardiovasc Intervent Radiol; 2019 Feb; 42(2):230-238. PubMed ID: 30488302
[TBL] [Abstract][Full Text] [Related]
58. Prognostic factors for survival in patients with unresectable hepatocellular carcinoma undergoing chemoembolization with doxorubicin drug-eluting beads: a preliminary study.
Dhanasekaran R; Kooby DA; Staley CA; Kauh JS; Khanna V; Kim HS
HPB (Oxford); 2010 Apr; 12(3):174-80. PubMed ID: 20590884
[TBL] [Abstract][Full Text] [Related]
59. Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm.
Su TS; Lu HZ; Cheng T; Zhou Y; Huang Y; Gao YC; Tang MY; Jiang HY; Lian ZP; Hou EC; Liang P
BMC Cancer; 2016 Nov; 16(1):834. PubMed ID: 27809890
[TBL] [Abstract][Full Text] [Related]
60. Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma.
Song MJ; Bae SH; Lee JS; Lee SW; Song DS; You CR; Choi JY; Yoon SK
Korean J Intern Med; 2016 Mar; 31(2):242-52. PubMed ID: 26874512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
